The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .
Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.
Low fibrinolytic activity , as measured by euglobulin ( EFA ) , has been observed in obese subjects , and hypofibrinolysis may play a role in the pathogenesis of atherosclerosis and its complications . Blood fibrinolytic activity is regulated through a complex system of activators and inhibitors , especially plasminogen activator inhibitors ( PA Inhibitors ) . In a group of 35 non-diabetic subjects with a wide range of body mass index ( BMI ) , EFA was negatively correlated , and PA Inhibitor activity positively correlated , with BMI and plasma insulin levels . In a population of 49 non-diabetic obese women ( differing from a control group of normal weight by lower EFA and higher level , of PA Inhibitor activity , plasma insulin and triglyceride ) , the PA Inhibitor activity was positively correlated with BMI , insulin and triglyceride . The increase in PA Inhibitor activity was associated with a high value of PA Inhibitor 1 antigen measured by an immuno-radiometric assay , indicating that the increased activity was due to a high level of circulating PA Inhibitor 1 . Plasma insulin was lowered in obese non-diabetic subjects , without modification of the body weight , by a 24 hour fast or by treatment with Metformin . After 24 hours ' fast , ten obese subjects had lower levels of insulin and PA Inhibitor activity and an increase in EFA . Treatment for 15 days by 1.75 g Metformin ( or placebo ) , on a weight maintaining diet , induced , in the Metformin group , a decrease in plasma insulin , triglyceride and PA Inhibitor activity and an increase in EFA , while no change was observed in the placebo group . ( ABSTRACT TRUNCATED AT 250 WORDS
The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .